We begin this week with news from Parexel – who could be expecting a future revenue boom according to an article this week – and the CRO has appointed a new Senior Vice President in the guise of Ingo Bank.
Bank, who will also become Chief Financial Officer on September 1, has spent the last 18 years with Royal Philips, holding numerous senior global finance positions, most recently CFO and Executive Vice President of Philips Healthcare
“Ingo’s business acumen and focus on continuous improvement and performance will serve us well as we drive our growth strategy and focus on continuing to deliver profitable results to our stakeholders,” said Josef von Rickenbach, CEO of Parexel.
He will replace James Winschel, Jr. in a role that – according to an SEC filing – will net him a base salary of $450,000 plus a signing bonus of $500,000.
CDMO DPT Laboratories has made two new appointments with new Business Development Manager for DPT’s Midwest Sales Territory Timothy O’Neill, and Business Development Manager focusing on new client development and sales growth for the company’s Northeast Sales Territory Kevin Kelly, joining the team.
“With their proven track records for building solid client relationships and driving growth, Tim and Kevin will play an important role as we maximize our semi-solid and liquid business in San Antonio, and achieve aggressive growth in sterile and specialty products business in Lakewood,” said DPT’s Sr. VP of Sales, Marketing and Corporate Development Paul Josephs.
O’Neill comes from Nipro Glass Americas and has 24 years industry experience.
Kelly has spent 19 years in the pharma world most recently serving as a Senior Account Executive at Fisher Clinical Services.
Not-for-profit scientific research organisation Southern Research Institute has announced Dr. Arthur Tipton has been selected by its Board of Directors to serve as president and CEO.
Previously serving as senior vice president and general manager of Evonik, Tipton will replace Dr. John "Jack" Secrist, III, who held the role for seven years.
Chairman of the Board Dr. Ray Watts said: “This is a critical time for research, with both opportunities and challenges, and his experience and strategic vision are ideal to grow the organization's portfolio of contract research in biomedical science, drug discovery and advanced technology/engineering.”
And lastly this week, another non-profit organisation Critical Path Institute has announced Dr. John-Michael Sauer has joined the company as Executive Director of the Predictive Safety Testing Consortium (PSTC).
Dr. Sauer, who has led research teams at Pfizer-CovX in California and Covance in Arizona, has a background which “will greatly add to the consortium’s collaborative efforts among industry and regulatory scientists,” according to C-Path CEO Martha brumfield.